Clinical Trial Update: A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple Sclerosis [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the effects of ocrelizumab on immune responses in participants with relapsing forms of multiple sclerosis has completed with results po…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis
• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Ocrelizumab (ocrelizumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Multiple Sclerosis, Relapsing-Remitting | Phase 3 | Status: COMPLETED | Results posted: 2018-06-06